Igenica Biotherapeutics

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Genomics-Proteomics
  • Pharmaceuticals
See more in Biomedtracker

Latest on Igenica Biotherapeutics

Scrip

Kineta Resumes Enrollment Of Anti-VISTA Antibody Trial

 
• By Joseph Haas

Kineta, Inc. and potential partner TuHura Biosciences revealed on 19 August that enrollment is resuming in the Phase I portion of a Phase I/II study of the anti-VISTA antibody KVA12123 in advanced

In Vivo

Deals Shaping The Medical Industry, June 2017

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

IN VITRO DIAGNOSTICS Financings Accelerate Diagnostics Inc. Infectious disease-focused Accelerate Diagnostics Inc. netted $74.6mm through the upsized follow-on offering of 2.75mm common shares pri

Scrip

Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

 
• By Joseph Haas, Jung Won Shin, Alex Shimmings, and Anju Ghangurde

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Scrip

Recent Financings of Private Companies, July-August 2012

 
• By Deanna Kamienski, Beth Allan, Andrea Mancini, Amanda Micklus, Maureen Riordan, and Theresa Surprenant

IN VITRO DIAGNOSTICS Agendia BV Agendia raises $65mm through late-stage round A year after withdrawing its IPO filing, molecular diagnostics firm Agendia BV has raised $65mm in what appears to